Ikarian Capital’s Cartesian Therapeutics RNAC Stock Holding History

Ikarian Capital’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217K	Hold	20,807	–	–	0.02%	138
2026 Q1	$128K	Hold	20,807	–	–	0.01%	146
2025 Q4	$150K	Sell	20,807 -1,359	-6%	-$11K	0.01%	158
2025 Q3	$227K	Hold	22,166	–	–	0.02%	150
2025 Q2	$230K	Hold	22,166	–	–	0.04%	108
2025 Q1	$292K	Sell	22,166 -30,000	-58%	-$536K	0.04%	130
2024 Q4	$934K	Sell	52,166 -27	-0.1%	-$547	0.13%	111
2024 Q3	$841K	Sell	52,193 -190,177	-78%	-$2.97M	0.12%	103
2024 Q2	$6.55M	Buy	+242,370	New	+$5.78M	1.14%	26

Other funds holding RNAC

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ikarian Capital's RNAC Position: Q2 2026 in Review

Ikarian Capital held its Cartesian Therapeutics (RNAC) position steady in Q2 2026 at 20,807 shares worth $217K. The position accounts for 0.02% of the portfolio, ranked #138.

Ikarian Capital first reported a position in RNAC in Q2 2024 and has held it in 9 quarters since. The position peaked at $6.55M in Q2 2024. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

Ikarian Capital held 20,807 shares of Cartesian Therapeutics worth $217K as of Q2 2026.
Ikarian Capital left its Cartesian Therapeutics share count unchanged in Q2 2026.
Cartesian Therapeutics made up 0.02% of Ikarian Capital's portfolio in Q2 2026, its #138 holding.
Ikarian Capital first reported a position in Cartesian Therapeutics in Q2 2024 and has held it in 9 quarters since.
Ikarian Capital's Cartesian Therapeutics position peaked at $6.55M in Q2 2024.
95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.